Top Medical News

Ocrelizumab Holds Benefit for Relapsing MS Patients With Prior Suboptimal DMT Response

September 22, 2020

By Marco Meglio

Treatment with ocrelizumab can improve freedom from individual events in patients with relapsing-remitting multiple sclerosis regardless of suboptimal DMT response in the past.

The Importance of Patient-Centered Care in Parkinson Disease

September 22, 2020

By Matt Hoffman

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of patient-focused interventions in PD.

Investigational Drug Targeting Epstein-Barr Virus Shows Promise for Progressive MS

September 21, 2020

By Matt Hoffman

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Progressive and Relapsing-Remitting Multiple Sclerosis Share Similar Fatigue Severity

September 21, 2020

By Marco Meglio

Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.

World Alzheimer’s Day 2020: The Latest News and Commentary on the Treatment of Alzheimer Disease

September 21, 2020

By Marco Meglio

In honor of World Alzheimer’s Day, NeurologyLive is sharing some of the latest clinical developments and thoughts from leaders in the field.

Featured

Latest Videos

Optimal Management of OFF Episodes in Parkinson's Disease

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020

Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS

The Changing Treatment Landscape for Acute Migraine

Jonathan Graff-Radford, MD: Efforts to Reduce Rates of Alzheimer Disease Dementia

Opicapone Treats Motor Fluctuations, Directional DBS Favored in PD, MRgFUS is Effective as Hand Tremor Treatment

Luc Truyen, MD, PhD: Long-Term Results of Ponesimod in Phase 2b Study

Indu Subramanian, MD: Social Prescribing for Patients With Parkinson Disease

Stewart Factor, MD: Long-Term Data on Apomorphine Sublingual Film in Parkinson

Asaff Harel, MD: Risk Factors for Severe COVID-19 Infection in Multiple Sclerosis

Joaquim Ferreria, MD, PhD: Opicapone’s Use in Levodopa-Treated Patients With Parkinson Disease

Mary Schroth, MD: Cure SMA’s Ongoing Advocacy Initiatives

Most Recent

Ganaxolone Meets Primary End Point in CDKL5 Deficiency Disorder Study

September 20, 2020

Article

Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.

Ocrelizumab Treatment Results in High NEDA Rates, Improvements in MS Symptoms

September 19, 2020

Article

A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.

NeurologyLive Friday 5 — September 18, 2020

September 18, 2020

Article

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.

The Metamorphosis of Migraine: Evidence and Epidemiology

September 18, 2020

Article

The ongoing fight to add to the epidemiologic understanding of migraine is explored in part 2 of this special 3-part multimedia series on the evolution of migraine care.

Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension

September 18, 2020

Article

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study

September 17, 2020

Article

The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.

Addressing Loneliness and Social Isolation in Patients With Parkinson Disease

September 17, 2020

Article

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

Article

Two posters presented at MS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment

September 16, 2020

Article

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

THN102 Is Safe, Improves Excessive Daytime Sleepiness in Parkinson Disease

September 16, 2020

Article

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.